Hinson JA, Monks TJ, Hong M, Highet RJ, Pohl LR
ISBN 978-1-61035-065-5
Preventing glucose absorption with phloridizin abolishes glucose-stimulated GIP secretion in healthy wild-type (Sykes et al., 1980) and Kir6.2 / mice (Ogata et al., 2014), even in the presence of a -methyl-D-glucopyranoside (Moriya et al., 2009)
PIONEER1 is a randomized, double-blind, placebo-controlled, multi-center Phase I clinical study that mainly evaluates the efficacy and safety of semaglutide in the treatment of patients with T2DM
semaglutide therapy in Franklin and Nolensville produces a predictable pattern of changes that unfolds over months, with appetite shifts visible in the first week, scale changes accelerating around weeks four to eight, and the largest single drops happening between months three and twelve